The objective of the Administrative Team at Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) is to provide outstanding administrative leadership, management and fiscal oversight for the activities of the 128 members of MCC in order to achieve the goals and mission of MCC. Services provided by the Administration Team include: (1) financial management of the Cancer Center Support Grant (CCSG), including budget preparation, and post-award management;(2) administrative oversight of shared resources;(3) pre- and post-award grants management for interdisciplinary center grants and pilot project awards;(4) financial management of cancer clinical research grants and contracts, as well as donor, state and institutional funds;(5) personnel management of 132 FTE who support the research mission of MCC;(6) planning, management and execution of all MCC research seminars, symposiums, scientific program retreats, and poster sessions;(7) scheduling and official record keeping of all MCC Leadership meetings;(8) planning, management and execution of all leadership planning and evaluation activities;(9) membership application and maintenance of records;(10) space management;(11) internal and external marketing, public relations, and communications;(12) fundraising, community activity and government relations;(13) cancer research faculty recruitment planning and related activities;and (14) procurement. The major change in the Administrative Team since the last CCSG review is the reorganization of the administrative infrastructure that resulted in the recruitment of Donna Berrier, MPA, as the Associate Director for Administration and Finance, effective September 2009;Robert Houlihan, DHA, as Director of Research Administration and Operations, effective October 2009.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016059-33
Application #
8662718
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
33
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Yamada, Akimitsu; Nagahashi, Masayuki; Aoyagi, Tomoyoshi et al. (2018) ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer. Mol Cancer Res 16:1059-1070
Cantwell, Marc T; Farrar, Jared S; Lownik, Joseph C et al. (2018) STAT3 suppresses Wnt/?-catenin signaling during the induction phase of primary Myf5+ brown adipogenesis. Cytokine 111:434-444
Aqbi, Hussein F; Wallace, Matthew; Sappal, Samay et al. (2018) IFN-? orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. J Leukoc Biol :
Volker, Sonja E; Hedrick, Shannon E; Feeney, Yvonne B et al. (2018) Cyclophilin A Function in Mammary Epithelium Impacts Jak2/Stat5 Signaling, Morphogenesis, Differentiation, and Tumorigenesis in the Mammary Gland. Cancer Res 78:3877-3887
Li, Xiaojiaoyang; Liu, Runping; Huang, Zhiming et al. (2018) Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans. Hepatology 68:599-615
Durant, Stephen T; Zheng, Li; Wang, Yingchun et al. (2018) The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv 4:eaat1719
Damle, S R; Martin, R K; Cockburn, C L et al. (2018) ADAM10 and Notch1 on murine dendritic cells control the development of type 2 immunity and IgE production. Allergy 73:125-136
Wang, Feng; Li, Hongyan; Markovsky, Ela et al. (2018) Pazopanib radio-sensitization of human sarcoma tumors. Oncotarget 9:9311-9324
Stokes, Nancy A; Stanciu, Cristina E; Brocato, Emily R et al. (2018) Simplification of complex DNA profiles using front end cell separation and probabilistic modeling. Forensic Sci Int Genet 36:205-212
Poklepovic, Andrew; Qu, Yuesheng; Dickinson, Molly et al. (2018) Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. Cardiooncology 4:

Showing the most recent 10 out of 586 publications